Literature DB >> 25473149

Histopathology of hepatocellular carcinoma.

Manuel Schlageter1, Luigi Maria Terracciano1, Salvatore D'Angelo1, Paolo Sorrentino1.   

Abstract

Hepatocellular carcinoma (HCC) is currently the sixth most common type of cancer with a high mortality rate and an increasing incidence worldwide. Its etiology is usually linked to environmental, dietary or life-style factors. HCC most commonly arises in a cirrhotic liver but interestingly an increasing proportion of HCCs develop in the non-fibrotic or minimal fibrotic liver and a shift in the underlying etiology can be observed. Although this process is yet to be completely understood, this changing scenario also has impact on the material seen by pathologists, presenting them with new diagnostic dilemmas. Histopathologic criteria for diagnosing classical, progressed HCC are well established and known, but with an increase in detection of small and early HCCs due to routine screening programs, the diagnosis of these small lesions in core needle biopsies poses a difficult challenge. These lesions can be far more difficult to distinguish from one another than progressed HCC, which is usually a clear cut hematoxylin and eosin diagnosis. Furthermore lesions thought to derive from progenitor cells have recently been reclassified in the WHO. This review summarizes recent developments and tries to put new HCC biomarkers in context with the WHOs reclassification. Furthermore it also addresses the group of tumors known as combined hepatocellular-cholangiocellular carcinomas.

Entities:  

Keywords:  Hepatocellular carinoma; Histology; Pathology

Mesh:

Substances:

Year:  2014        PMID: 25473149      PMCID: PMC4239483          DOI: 10.3748/wjg.v20.i43.15955

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  66 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection.

Authors:  H Huang; H Fujii; A Sankila; B M Mahler-Araujo; M Matsuda; G Cathomas; H Ohgaki
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.

Authors:  Xiao Ying Wang; Françoise Degos; Sylvie Dubois; Sandrine Tessiore; Mark Allegretta; Ronald D Guttmann; Serge Jothy; Jacques Belghiti; Pierre Bedossa; Valérie Paradis
Journal:  Hum Pathol       Date:  2006-08-10       Impact factor: 3.466

4.  Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.

Authors:  Marcela Salomao; Woojin M Yu; Robert S Brown; Jean C Emond; Jay H Lefkowitch
Journal:  Am J Surg Pathol       Date:  2010-11       Impact factor: 6.394

5.  Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma.

Authors:  Makoto Shibuya; Fukuo Kondo; Keiji Sano; Tadahiro Takada; Takehide Asano
Journal:  J Hepatobiliary Pancreat Sci       Date:  2011-07       Impact factor: 7.027

6.  Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.

Authors:  Luca Di Tommaso; Giada Franchi; Young Nyun Park; Barbara Fiamengo; Annarita Destro; Emanuela Morenghi; Marco Montorsi; Guido Torzilli; Maurizio Tommasini; Luigi Terracciano; Luigi Tornillo; Raffaella Vecchione; Massimo Roncalli
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

7.  Hepatocellular carcinoma with lymphoid stroma: a tumour with good prognosis after liver transplantation.

Authors:  J F Emile; R Adam; M Sebagh; E Marchadier; B Falissard; E Dussaix; H Bismuth; M Reynès
Journal:  Histopathology       Date:  2000-12       Impact factor: 5.087

8.  Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.

Authors:  Sanjay Kakar; Trudie Muir; Linda M Murphy; Ricardo V Lloyd; Lawrence J Burgart
Journal:  Am J Clin Pathol       Date:  2003-03       Impact factor: 2.493

9.  The morphologic transition in hepatocellular carcinoma. A comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy.

Authors:  S Sugihara; O Nakashima; M Kojiro; Y Majima; M Tanaka; K Tanikawa
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

Review 10.  Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis.

Authors:  M Anzola
Journal:  J Viral Hepat       Date:  2004-09       Impact factor: 3.728

View more
  54 in total

1.  Expression of receptor interacting protein 1 and receptor interacting protein 3 oval cells in a rat model of hepatocarcinogenesis.

Authors:  Marta Wójcik; Ryszard Bobowiec; Urszula Lisiecka; Anna Śmiech
Journal:  Exp Ther Med       Date:  2018-03-22       Impact factor: 2.447

Review 2.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

3.  Automatic quantification of morphological features for hepatic trabeculae analysis in stained liver specimens.

Authors:  Masahiro Ishikawa; Yuri Murakami; Sercan Taha Ahi; Masahiro Yamaguchi; Naoki Kobayashi; Tomoharu Kiyuna; Yoshiko Yamashita; Akira Saito; Tokiya Abe; Akinori Hashiguchi; Michiie Sakamoto
Journal:  J Med Imaging (Bellingham)       Date:  2016-06-03

4.  Exposure to growth hormone is associated with hepatic up-regulation of cPLA2α and COX.

Authors:  Verónica G Piazza; María E Matzkin; Nadia S Cicconi; Nadia V Muia; Sofía Valquinta; Gregorio J Mccallum; Giannina P Micucci; Thomas Freund; Elsa Zotta; Lorena González; Mónica B Frungieri; Yimin Fang; Andrzej Bartke; Ana I Sotelo; Johanna G Miquet
Journal:  Mol Cell Endocrinol       Date:  2020-04-04       Impact factor: 4.102

5.  The clinicopathological significance of miR-149 and PARP-2 in hepatocellular carcinoma and their roles in chemo/radiotherapy.

Authors:  Ling Lin; Yang-de Zhang; Zi-Yu Chen; Yuxiang Chen; Cai-Ping Ren
Journal:  Tumour Biol       Date:  2016-06-14

6.  The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.

Authors:  Osama H Labib; Ola A Harb; Osama H Khalil; Taha A Baiomy; Loay M Gertallah; Rham Z Ahmed
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 7.  Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.

Authors:  Jian-Jun Gao; Zhen-Yan Shi; Ju-Feng Xia; Yoshinori Inagaki; Wei Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

8.  The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma.

Authors:  Martin K Thomsen; Morten K Skouboe; Cedric Boularan; Fabienne Vernejoul; Thierry Lioux; Siv L Leknes; Martin F Berthelsen; Maria Riedel; Huiqiang Cai; Justin V Joseph; Eric Perouzel; Michele Tiraby; Mikkel H Vendelbo; Søren R Paludan
Journal:  Oncogene       Date:  2019-11-18       Impact factor: 9.867

9.  Inhibitory and ameliorative effect of heliomycin derived from actinomycete on induced hepatocellular carcinoma in rats.

Authors:  Ahmed S Alazzouni; Abdulla A Mahmoud; Mohamed M Omran; Ehab A Essawy; Mohga S Abdalla; Mohamed S Abdelfattah
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-01-08       Impact factor: 3.000

10.  Clinicopathological features and surgical outcomes of four rare subtypes of primary liver carcinoma.

Authors:  Zhiyu Li; Xiaolong Wu; Xinyu Bi; Yefan Zhang; Zhen Huang; Haizhen Lu; Hong Zhao; Jianjun Zhao; Jianguo Zhou; Muxing Li; Jianming Ying; Jianqiang Cai
Journal:  Chin J Cancer Res       Date:  2018-06       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.